Erlotinib in the Second/Third Line Treatment of Patients with Advanced Non-small Cell Lung Cancer

Erlotinib in the Second/Third Line Treatment of Patients with Advanced Non-small Cell Lung Cancer

Background and objective Erlotinib is a targeted drug for non-small cell lung cancer (NSCLC). The aim of this study is to evaluate the efficacy, influencing factors and toxicity of erlotinib in patients with NSCLC. Methods Patients with NSCLC who had been previously treated with at least one course...

Full description

Bibliographic Details
Main Authors: Yilong WU, Zhen WANG, Chongrui XU, Jinji YANG, Qing ZHOU, Yujuan HUANG, Yisheng HUANG
Format: Article
Language:zho
Published: Chinese Anti-Cancer Association; Chinese Antituberculosis Association 2009-05-01
Series:Chinese Journal of Lung Cancer
Subjects:
Lung neoplasms
Erlotinib
Online Access:http://www.lungca.org/index.php?journal=01&page=article&op=view&path%5B%5D=10.3779%2Fj.issn.1009-3419.2009.05.019&path%5B%5D=821

Internet

http://www.lungca.org/index.php?journal=01&page=article&op=view&path%5B%5D=10.3779%2Fj.issn.1009-3419.2009.05.019&path%5B%5D=821

Similar Items